TABLE 3.
Follow-up Clinical and Endoscopic Outcomes in Patients with UC by Severity Group
| Overall UC (n = 601) | Mild UC (n = 78) | Moderate UC (n = 273) | Severe UC (n = 250) | P | |
|---|---|---|---|---|---|
| Length of follow-up, mo | 162 (8–683) | 162 (42–494) | 180 (20–683) | 138 (8–594) | 0.0004 |
| Median number of endoscopic procedures | 3 (1–5) | 4 (1–5) | 3 (1–5) | 2 (1–5) | <0.0001 |
| Need for colectomy (%) | NA | ||||
| Yes | 385 (64) | 10 (13) | 167 (61) | 208 (83) | |
| No | 216 (36) | 68 (87) | 106 (39) | 42 (17) | |
| Colectomy indication (%) | NA | ||||
| IV steroid failure | 139 | 0 | 0 | 139 | |
| Megacolon | 21 | 0 | 0 | 21 | |
| Massive bleeding | 5 | 0 | 0 | 5 | |
| Chronic disease | 190 | 0 | 149 | 41 | |
| Cancer/dysplasia | 30 | 10 | 18 | 2 | |
| Time from diagnosis to colectomy (mo) | 60 (0–469) | 185 (60–303) | 97 (11–469) | 30 (0–436) | <0.0001 |
| Oral prednisone (%) | NA | ||||
| Yes | 498 (83) | 11 (14) | 264 (97) | 224 (90) | |
| No | 80 (13) | 64 (82) | 8 (3) | 8 (3) | |
| Unknown | 23 (4) | 3 (4) | 1 (0) | 18 (7) | |
| Prednisone duration (%) | NA | ||||
| Up to 3 mo | 8 (12) | 9 (12) | 8 (3) | 41 (19) | |
| 3–12 mo | 150 (32) | 0 | 68 (27) | 82 (39) | |
| More than 1 yr | 261 (55) | 0 | 173 (69) | 88 (42) | |
| Time from diagnosis to 1st prednisone (range), mo | 56 (0–424) | 48 (0–372) | 22 (0–618) | 5 (0–413) | 0.0004 |
| AZA/6-MP (%) | 31 (5) | 2 (3) | 20 (7) | 9 (4) | NA |
| Effective long term | 31 (5) | 2 (3) | 20 (7) | 9 (4) | |
| Stopped—ineffective | 108 (18) | 0 | 68 (25) | 40 (16) | |
| Stopped—AE | 68 (11) | 0 | 47 (17) | 21 (8) | |
| Never prescribed | 377 (63) | 76 (97) | 135 (50) | 166 (66) | |
| Unknown | 17 (3) | 0 | 3 (1) | 14 (6) | |
| TNF-α antagonists (%) | NA | ||||
| IFX effective | 35 (6) | 0 | 23 (8) | 12 (5) | |
| ADA effective | 7 (1) | 0 | 6 (2) | 1 (0) | |
| Ineffective | 41 (7) | 0 | 19 (7) | 22 (9) | |
| Never prescribed | 513 (85) | 77 (99) | 224 (82) | 212 (85) | |
| Unknown | 5 (1) | 1 (1) | 1 (0) | 3 (1) | |
| 5-ASA (%) | NA | ||||
| Effective long term | 139 (23) | 70 (90) | 49 (18) | 20 (8) | |
| Stopped—ineffective | 411 (69) | 6 (8) | 205 (75) | 201 (80) | |
| Stopped—AE | 30 (5) | 2 (2) | 16 (6) | 12 (5) | |
| Never prescribed | 11 (2) | 0 | 1 (0) | 10 (4) | |
| Unknown | 10 (2) | 0 | 2 (1) | 7 (3) | |
| PSC (%) | 0.19 | ||||
| Yes | 22 (4) | 4 (5) | 11 (4) | 7 (3) | |
| No | 565 (94) | 70 (90) | 259 (95) | 236 (94) | |
| Unknown | 14 (2) | 4 (5) | 3 (1) | 7 (3) | |
| EIM (%) | 0.13 | ||||
| Yes | 397 (66) | 45 (58) | 190 (70) | 162 (65) | |
| No | 204 (34) | 33 (42) | 83 (30) | 88 (35) | |
| Median time to colectomy, mo | 60 | 185 | 97 | 30 | <0.0001 |
| Median time to extension, mo | 56 | 75 | 74 | 37 | 0.03 |
| Median time to 1st oral CS, mo | 56 | 48 | 22 | 5 | 0.0004 |
ADA, adalimumab; AE, adverse effect; ASA, amino salicylic acid; AZA, azathioprine; EIM, extraintestinal manifestations; IFX, infliximab; IV, intravenous; 6-MP, 6-mercaptopurine; PSC, primary sclerosing cholangitis.